Publications by authors named "Mai Atique"
Article Synopsis
- * A review of 55 clinical trials showed that 83.3% were conducted after 2015, mainly in the U.S., focusing on various FDA-approved drugs for HNC, including cetuximab and pembrolizumab.
- * There is a need for new drugs specifically for HPV-associated OPC, as the molecular mechanisms and outcomes differ from HPV-negative cases; researchers have identified mutated genes in HPV-positive OPC that could be targeted for future drug development.
(1) Background: Head and neck cancer (HNC) ranks as the sixth most prevalent cancer in the world. In addition to the traditional risk factors such as alcohol and tobacco consumption, the implication of the human papillomavirus (HPV) is becoming increasingly significant, particularly in oropharyngeal cancer (OPC). (2) Methods: This study is based on a review analysis of different articles and repositories investigating the mutation profile of HPV-related OPC and its impact on patient outcomes.
View Article and Find Full Text PDF